Institutional members access full text with Ovid®

Share this article on:

Autoimmune Myopathies

Mammen, Andrew L. MD, PhD

doi: 10.1212/01.CON.0000511070.50715.ab
Review Articles

ABSTRACT: Purpose of Review: This article provides guidelines for diagnosing and treating the different subtypes of autoimmune myopathies.

Recent Findings: The most common subtypes of autoimmune myopathies are dermatomyositis, immune-mediated necrotizing myopathy, antisynthetase syndrome, and overlap syndromes; isolated polymyositis is an exceptionally rare disease. Specific autoantibodies are associated with unique clinical phenotypes and may be used for diagnostic and prognostic purposes, such as to assess the risk of coexisting malignancy.

Summary: Diagnosing the specific subtype of autoimmune myopathy can be achieved by combining relevant features of the history, neuromuscular examination, muscle biopsy, and serologic studies.

Address correspondence to Dr Andrew L. Mammen, Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 50 South Dr, Room 1146, Bldg 50, MSC 8024, Bethesda, MD 20892, andrew.mammen@nih.gov.

Relationship Disclosure: Dr Mammen receives intramural research funding from the National Institutes of Health.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Mammen discusses the unlabeled/investigational use of azathioprine, cyclophosphamide, cyclosporine, IV immunoglobulin, methotrexate, methylprednisolone, mycophenolate mofetil, prednisone, rituximab, and tacrolimus for the treatment of autoimmune myopathies.

© 2016 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website